Effects of Silibinin Against Prothrombin Kringle-2-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System In Vivo.

Parkinson's disease (PD) and Alzheimer's disease exhibit common features of neurodegenerative diseases and can be caused by numerous factors. A common feature of these diseases is neurotoxic inflammation by activated microglia, indicating that regulation of microglial activation is a potential mechanism for preserving neurons in the adult brain. Recently, we reported that upregulation of prothrombin kringle-2 (pKr-2), one of the domains that make up prothrombin and which is cleaved and generated by active thrombin, induces nigral dopaminergic (DA) neuronal death through neurotoxic microglial activation in the adult brain. In this study, we show that silibinin, a flavonoid found in milk thistle, can suppress the production of inducible nitric oxide synthase and neurotoxic inflammatory cytokines, such as interleukin-1β and tumor necrosis factor-α, after pKr-2 treatment by downregulating the extracellular signal-regulated kinase signaling pathway in the mouse substantia nigra. Moreover, as demonstrated by immunohistochemical staining, measurements of the dopamine and metabolite levels, and open-field behavioral tests, silibinin treatment protected the nigrostriatal DA system resulting from the occurrence of pKr-2-triggered neurotoxic inflammation in vivo. Thus, we conclude that silibinin may be beneficial as a natural compound with anti-inflammatory effects against pKr-2-triggered neurotoxicity to protect the nigrostriatal DA pathway and its properties, and thus, may be applicable for PD therapy.

[1]  V. Tiwari,et al.  Neuroprotective effects of silibinin: an in silico and in vitro study , 2018, The International journal of neuroscience.

[2]  Y. Oh,et al.  Beneficial Effects of Silibinin Against Kainic Acid-induced Neurotoxicity in the Hippocampus in vivo , 2017, Experimental neurobiology.

[3]  T. Ikejima,et al.  Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress , 2016, Neurochemical Research.

[4]  Sang Ryong Kim,et al.  Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic System , 2016, Experimental neurobiology.

[5]  Control of Granule Cell Dispersion by Natural Materials Such as Eugenol and Naringin: A Potential Therapeutic Strategy Against Temporal Lobe Epilepsy. , 2016, Journal of medicinal food.

[6]  Myungwon Jin,et al.  Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System , 2016, The Journal of Neuroscience.

[7]  Sang Ryong Kim,et al.  Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system. , 2016, The Journal of nutritional biochemistry.

[8]  Jia-wei Zhou,et al.  Neuroinflammation in Parkinson’s disease and its potential as therapeutic target , 2015, Translational Neurodegeneration.

[9]  Sang-Joon Park,et al.  Induction of microglial toll-like receptor 4 by prothrombin kringle-2: a potential pathogenic mechanism in Parkinson’s disease , 2015, Scientific Reports.

[10]  Yu Sun,et al.  Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis , 2015, Journal of receptor and signal transduction research.

[11]  Yujeong Lee,et al.  Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease via mitochondrial stabilization , 2015, Journal of neuroscience research.

[12]  Yi Ding,et al.  Silibinin Prevents Autophagic Cell Death upon Oxidative Stress in Cortical Neurons and Cerebral Ischemia-Reperfusion Injury , 2015, Molecular Neurobiology.

[13]  R. Burke,et al.  Induction of GDNF and BDNF by hRheb(S16H) Transduction of SNpc Neurons: Neuroprotective Mechanisms of hRheb(S16H) in a Model of Parkinson’s Disease , 2014, Molecular Neurobiology.

[14]  Myung‐Sook Choi,et al.  Silibinin attenuates MPP⁺-induced neurotoxicity in the substantia nigra in vivo. , 2014, Journal of medicinal food.

[15]  Rudi Balling,et al.  The hallmarks of Parkinson's disease , 2013, The FEBS journal.

[16]  R. Burke,et al.  AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  N. Hattori,et al.  Molecular pathogenesis of Parkinson's disease: update , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  P. Bosco,et al.  Neuroprotective effect of silibinin in diabetic mice , 2011, Neuroscience Letters.

[19]  T. Nabeshima,et al.  Silibinin prevents amyloid β peptide‐induced memory impairment and oxidative stress in mice , 2009, British journal of pharmacology.

[20]  J. Jankovic Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  E. Ling,et al.  Microglial activation and its implications in the brain diseases. , 2007, Current medicinal chemistry.

[22]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[23]  Wan-Wan Lin,et al.  Silymarin protects dopaminergic neurons against lipopolysaccharide‐induced neurotoxicity by inhibiting microglia activation , 2002, The European journal of neuroscience.